• COMPASS Pathways Receives FDA Approval for Psilocybin Trial americanpharmaceuticalreview
    August 23, 2018
    COMPASS Pathways has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory approvals for the trial have already been given in the UK, the Netherlands and
PharmaSources Customer Service